SLC5A2 and Hypoglycemia: Similarly, studies performed in different populations with T1D have proved that the combination of insulin plus SGLT2 inhibitors (dapagliflozin/empagliflozin) could improve the control of blood glucose and body weight without increasing the risk of hypoglycemia (55–57).